Enzymotec (ENZY) Tops Q3 EPS by 1c; Guides FY15 EPS Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Enzymotec Ltd. Reports Third Quarter 2015 Results
November 11, 2015 7:30 AM ESTEarns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
VAYA Pharma Generates Record Net Revenues of $2.2 Million
MIGDAL HA'EMEQ, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the third quarter ended September 30, 2015.
Third Quarter Financial Highlights
Third quarter net revenues (equity method) increased 30.7% to $12.4 million, compared to the third quarter of 2014. Third quarter net revenues (proportionate... MoreEnzymotec Ltd. Reports Third Quarter 2015 Results
November 11, 2015 7:30 AM ESTEarns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
VAYA Pharma Generates Record Net Revenues of $2.2 Million
MIGDAL HA'EMEQ, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the third quarter ended September 30, 2015.
Third Quarter Financial Highlights
Third quarter net revenues (equity method) increased 30.7% to $12.4 million, compared to the third quarter of 2014. Third quarter net revenues (proportionate... More